Pulmonary arterial hypertension (PAH) is a progressive disease of the pulmonary vascular bed, and right heart failure is the leading cause of death. Treatment with vasoactive agents is crucial for these patient groups. We aimed to evaluate our treatment approach in patients with PAH patients as a tertiary centre.